Cantor Fitzgerald Forecasts BBIO FY2025 Earnings

BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for BridgeBio Pharma in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings of ($4.50) per share for the year. The consensus estimate for BridgeBio Pharma's current full-year earnings is ($2.56) per share.

Other equities research analysts also recently issued reports about the company. Bank of America increased their price objective on BridgeBio Pharma from $42.00 to $45.00 and gave the company a "buy" rating in a report on Monday, November 25th. HC Wainwright reiterated a "buy" rating and set a $49.00 price target on shares of BridgeBio Pharma in a research note on Monday, December 16th. Scotiabank raised their price objective on shares of BridgeBio Pharma from $45.00 to $48.00 and gave the stock a "sector outperform" rating in a research report on Monday, November 25th. Oppenheimer initiated coverage on shares of BridgeBio Pharma in a report on Thursday, October 3rd. They issued a "market perform" rating for the company. Finally, Evercore ISI raised their price target on BridgeBio Pharma from $45.00 to $50.00 and gave the stock an "outperform" rating in a report on Monday, December 23rd. Two research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company's stock. According to data from MarketBeat.com, BridgeBio Pharma presently has an average rating of "Moderate Buy" and an average price target of $48.08.

BridgeBio Pharma Trading Up 3.5 %

Shares of NASDAQ BBIO traded up $1.25 during trading hours on Thursday, reaching $37.09. The stock had a trading volume of 1,402,900 shares, compared to its average volume of 3,125,286. The firm has a market cap of $7.01 billion, a price-to-earnings ratio of -15.39 and a beta of 1.05. BridgeBio Pharma has a fifty-two week low of $21.62 and a fifty-two week high of $41.04. The firm has a 50-day moving average of $28.27 and a 200-day moving average of $26.74.

Insider Activity

In other news, CEO Neil Kumar sold 27,389 shares of the firm's stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $22.41, for a total transaction of $613,787.49. Following the completion of the transaction, the chief executive officer now directly owns 4,897,443 shares of the company's stock, valued at $109,751,697.63. This trade represents a 0.56 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Brian C. Stephenson sold 4,156 shares of the company's stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $22.41, for a total value of $93,135.96. Following the completion of the sale, the chief financial officer now directly owns 93,758 shares in the company, valued at approximately $2,101,116.78. The trade was a 4.24 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 24.66% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in BBIO. Atomi Financial Group Inc. acquired a new stake in BridgeBio Pharma during the fourth quarter worth approximately $392,000. Moss Adams Wealth Advisors LLC acquired a new stake in shares of BridgeBio Pharma during the fourth quarter worth $208,000. Avanza Fonder AB purchased a new stake in shares of BridgeBio Pharma in the fourth quarter valued at $181,000. Principal Financial Group Inc. increased its stake in BridgeBio Pharma by 1.8% in the third quarter. Principal Financial Group Inc. now owns 1,145,123 shares of the company's stock valued at $29,155,000 after purchasing an additional 19,978 shares during the last quarter. Finally, Exome Asset Management LLC lifted its position in BridgeBio Pharma by 167.4% during the third quarter. Exome Asset Management LLC now owns 211,000 shares of the company's stock worth $5,372,000 after buying an additional 132,093 shares during the period. Institutional investors and hedge funds own 99.85% of the company's stock.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.